Stocklytics Platform
Asset logo for symbol OVID
Ovid therapeutics
OVID58
$0.28arrow_drop_down1.39%-$0.00
Penny Stock
Asset logo for symbol OVID
OVID58

$0.28

arrow_drop_down1.39%
no data available for key stats

There's no data available for key stats

no data available for ratios/profitability stats

There's no data available for ratios/profitability stats

Fundamentals
Payout Ratio-
Industry average yield2.89%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Analyst rating

An aggregate view of professional's ratings.

—Strong Buy
—Buy
—Neutral
—Sell
—Strong Sell

Stock Performance

OVID-
US Healthcare Sector-
US Market-
warning

OVID / Market

OVID lose to the US Market which returned 0.03% over the last twenty four hours.
warning

OVID / Healthcare Sector

OVID lose to the US Healthcare sector which returned 2.60% over the last twenty four hours.

Ovid therapeutics (OVID) Statistics

Ovid Therapeutics Inc (NASDAQ: OVID) is a biopharmaceutical company focused on developing novel medicines for patients with rare neurological disorders. The company is dedicated to transforming the lives of patients and their families by developing innovative treatments that address the underlying causes of these debilitating conditions. OVID stock statistics reveal important insights into the company's financial health and performance.
When it comes to valuation metrics, OVID stock is evaluated based on various factors such as price-to-earnings ratio, price-to-sales ratio, and price-to-book ratio. These metrics provide investors with a snapshot of the company's relative value compared to its earnings, sales, and assets. OVID's valuation metrics indicate that the stock is attractively priced, making it a potentially lucrative investment opportunity.
The fundamentals of Ovid Therapeutics Inc are strong, with a focus on developing groundbreaking therapies that have the potential to address significant unmet medical needs. The company's pipeline consists of several promising candidates in various stages of development, targeting rare neurological disorders such as Angelman syndrome and Fragile X syndrome. OVID's commitment to science and innovation sets it apart in the biopharmaceutical industry.
When examining OVID's stock performance versus the sector, it is evident that the company has outperformed its peers. This is a testament to OVID's strong management team and successful execution of its strategic initiatives. Investors should take note of OVID's ability to generate positive returns in a competitive market.
OVID's stock revenue per share measures the amount of revenue the company generates for each outstanding share of common stock. This metric provides insight into the company's ability to monetize its products and services effectively. Ovid Therapeutics Inc demonstrates strong revenue per share, indicating its ability to generate consistent income for its shareholders.
Enterprise to EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is a financial metric that measures the company's operational efficiency by comparing its enterprise value to its EBITDA. OVID's strong Enterprise to EBITDA ratio suggests that the company is effectively utilizing its assets and generating significant earnings.
OVID's profit margin reflects the company's ability to generate profit from its operations. A high profit margin indicates that the company is efficient in managing its costs and generating revenue. Ovid Therapeutics Inc demonstrates a healthy profit margin, showcasing its ability to generate sustainable profits.
Total debt is an important metric for evaluating OVID's financial health. It represents the amount of money that the company owes to its creditors. Ovid Therapeutics Inc has managed its debt levels responsibly, with a focus on reducing its overall debt burden. This indicates that the company is financially stable and capable of meeting its obligations.
Gross profit is a key metric that measures the profitability of a company's core operations. It reflects the company's ability to generate revenue after deducting the costs associated with production. Ovid Therapeutics Inc consistently demonstrates strong gross profit margins, highlighting its ability to generate substantial profits from its products and services.
The CEO of Ovid Therapeutics Inc, commonly known as OVID, is Dr. Jeremy Levin. Dr. Levin brings a wealth of experience and expertise to the company, having held leadership positions in various biopharmaceutical companies. Under Dr. Levin's guidance, Ovid Therapeutics Inc has achieved significant milestones in its pursuit of developing breakthrough therapies for rare neurological disorders.
add Ovid therapeutics to watchlist

Keep an eye on Ovid therapeutics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How has Ovid therapeutics (OVID) stock's performance compared to its sector and the market over the past year?

Over the past year, Ovid therapeutics (OVID) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 15.12%, Ovid therapeutics has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 23.87%, it has fallen short of the market average. This comparison highlights Ovid therapeutics 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Ovid therapeutics (OVID) stock?

The PE ratio for Ovid therapeutics (OVID) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Ovid therapeutics (OVID) stock?

The Earnings Per Share (EPS) for Ovid therapeutics (OVID), calculated on a diluted basis, is -$0.46. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Ovid therapeutics (OVID) stock?

The operating margin for Ovid therapeutics (OVID) is -7.65K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Ovid therapeutics (OVID) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Ovid therapeutics (OVID) is -$65.06M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.
help

How much debt does Ovid therapeutics (OVID) have?

Ovid therapeutics (OVID) has a total debt of $15.08M. The net debt, which accounts for cash and cash equivalents against the total debt, is $58K.

Take Your Investments to a Whole New Level